30 September 2026

Oncoinvent ASA – Mandatory notification of trade – Return of lent shares following Private Placement

Oslo, 30 September 2026: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the “Company”) on 22 September 2026 regarding completion of a private placement and retail offering of in total 1,650,000 new shares at a subscription price of NOK 90 per share (the “Private Placement”), and the mandatory notification of trade and shareholding disclosure published on 23 September 2026 regarding the allocation of new shares to, and temporary share lending by, Hadean Capital I AS, HVentures Capital I AB and Hadean Growth Fund I AS.

In connection with the Private Placement, Hadean Capital I AS, HVentures Capital I AB and Hadean Growth Fund I AS temporarily lent an aggregate of 554,327 existing and unencumbered shares in the Company to ABG Sundal Collier ASA and DNB Carnegie, a part of DNB Bank ASA, acting as managers in the Private Placement (the “Managers”), solely to facilitate delivery-versus-payment (“DVP”) settlement of shares allocated to investors in the Private Placement. Following registration of the share capital increase pertaining to the Private Placement with the Norwegian Register of Business Enterprises, the Managers have now re-delivered the temporarily lent shares to the aforementioned share lenders.

Hadean Capital I AS

The Managers have re-delivered 312,280 shares in the Company to Hadean Capital I AS. Following re-delivery of the temporarily lent shares and delivery of the 108,469 new shares allocated to Hadean Capital I AS in the Private Placement, Hadean Capital I AS holds 420,749 shares and votes in the Company, equal to 6.87% of the total number of shares and votes in the Company, thereby crossing above the 5% reporting threshold pursuant to the Norwegian Securities Trading Act (the “NSTA”), as also described in the announcement made on 23 September 2026.

HVentures Capital I AB

The Managers have re-delivered 141,642 shares in the Company to HVentures Capital I AB. Following re-delivery of the temporarily lent shares and delivery of the 49,199 new shares allocated to HVentures Capital I AB in the Private Placement, HVentures Capital I AB holds 190,841 shares and votes in the Company, equal to 3.11% of the total number of shares and votes in the Company, as also described in the announcement made on 23 September 2026.

Hadean Growth Fund I AS

The Managers have re-delivered 100,405 shares in the Company to Hadean Growth Fund I AS. Following re-delivery of the temporarily lent shares and delivery of the 34,875 new shares allocated to Hadean Growth Fund I AS in the Private Placement, Hadean Growth Fund I AS holds 135,280 shares and votes in the Company, equal to 2.21% of the total number of shares and votes in the Company, as also described in the announcement made on 23 September 2026.

Following re-delivery of all temporarily lent shares and the shares allocated in the Private Placement, Hadean Capital I AS, HVentures Capital I AB and Hadean Growth Fund I AS hold an aggregate of 746,870 shares and votes in the Company, equal to 12.19% of the total number of shares and votes in the Company, thereby crossing above the 5% and 10% reporting thresholds pursuant to the NSTA on a consolidated basis, as also described in the announcement made on 23 September 2026.

Hadean Capital I AS, HVentures Capital I AB and Hadean Growth Fund I AS are persons closely associated with Ingrid Teigland Akay, member of the Board of Directors of the Company and Managing Partner of Hadean Ventures.

See the attached PDMR forms for further information.

PDMR attachment.pdf

This information is subject to the disclosure requirements in article 19 of Regulation (EU) No 596/2014 (the EU Market Abuse Regulation) and section 4-2 of the NSTA.

* * *

PDMR attachment vF



Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close